Arellano-Aguilar G, Núñez-Mojica ES, Gutiérrez-Velazco JL, Domínguez-Carrillo LG

Language: Spanish
References: 15
Page: 79-83
PDF size: 371.29 Kb.

ABSTRACT

Background: Neurological paraneoplastic syndromes are rare, occur in 0.01% of all cancer patients; like part of them, the Lambert-Eaton syndrome is an autoimmune presynaptic disorder of neuromuscular transmission characterized by muscle weakness and neurovegetative dysfunction, and often associated with small cell lung cancer. Case report: A 72 years old female with a family history of lung cancer and leukemia, with 7 months of dry cough and 3 months with waist and pelvic muscle weakness, oropharyngeal dysphagia, dry mouth, chronic constipation and weight loss of 10 kg. Physical examination: patient prostrated; clinical muscle examination: pelvic muscles waist −3/5 and −4/5 the rest; diminished reflexes. Laboratory normal parathormone and hypercalcemia. With electrophysiological study and positive anti-voltage-gated calcium channel antibodies, confirming Lambert-Eaton syndrome and imaging studies with neoplastic condition in brain, liver and kidney, with unspecified primary origin.

REFERENCES

1. Auche M. Des nevrites peripheriques chez les cancereux. Rev Med. 1890;10:785-807.

2. Grausa F, Dalmaua J. Paraneoplastic neurological syndromes Curr Opin Neurol. 2012;25:795-801.

3. Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27:489-95.

4. Braik T, Evans AT, Telfer M, McDunn S. Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review. Am J Med Sci. 2010;340:301-8.

5. Anderson HJ, Churchill DH, Richardson AT. Bronchial neoplasm with myasthenia, prolonged apnea after administration of succinylcholine. Lancet. 1953;265:1291-3.

6. Eaton LM, Lambert EH. Electromyography and electrical stimulation of nerves in disease of the motor unit: observations on a myasthenic syndrome associated with malignant tumors. JAMA. 1957;163:1117-24.

7. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol. 2003;250:698-701.

8. Fernández-Torrón R, Arcocha J, López-Picazo JM, et al. Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies. Neuromuscul Disord. 2011;21:126-8.

9. Motomura M, Lang B, Johnston I, et al. Incidence of serum anti-P/Qtype and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147:35-42.

10. Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27:4260-7.

11. AAEM Quality Assurance Committee. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24:1236-8.

12. Pellkofer HL, Armbruster L, Krumbholz M, et al. Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol. 2008; 204:136-9.

13. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010; 17:893-902.

14. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82:671-3.

15. Wirtz PW, Smallegaange TM, Wintzen AR, et al. Difference in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. J Neurol Neurosurg Psychiatry. 2002;104:359-63.